EXHIBIT 99.1
Published on August 1, 2024
Exhibit 99.1
NEWS RELEASE
FOR IMMEDIATE RELEASE
Concentra Group Holdings Parent, Inc. Announces Results
For Its Second Quarter Ended June 30, 2024
ADDISON, TEXAS — August 1, 2024 — Concentra Group Holdings Parent, Inc. (“Concentra,” “we,” “us,” or “our”) (NYSE: CON) today announced results for its second quarter ended June 30, 2024.
“Our colleagues’ ongoing commitment to providing exceptional service and care continues to be the powerful force driving Concentra forward. With steadfast dedication to our mission to improve the health of America’s workforce, one patient at a time, we have reached another important milestone with the completion of our IPO,” said Keith Newton, Chief Executive Officer of Concentra.
Matt DiCanio, President & Chief Financial Officer, added “We are so proud of our colleagues and teams who have provided great care and dedication over the past 45 years. Our IPO marks a significant landmark in our company’s history, but it does not change our goal of meeting and exceeding customer and patient needs and delivering consistent financial results. We are confident in our ability to continue to drive optimal performance now and into the future.”
Second Quarter 2024 Highlights
For the second quarter ended June 30, 2024 and 2023
| · | Revenue of $477.9 million, an increase of 2.3% from $467.1 million in Q2 2023 | |
| · | Net Income of $53.1 million, a decrease of 1.8% from $54.0 million in Q2 2023 | |
| · | Adjusted EBITDA of $101.6 million, an increase of 1.2% from $100.4 million in Q2 2023 | |
| · | Earnings per Share of $0.50, a decrease of 2.0% from $0.51 in Q2 2023 | |
| · | Patient Visits of 3,214,255, or 50,223 Visits per Day in the quarter, a decrease of 1.6% from Q2 2023 | |
| · | Revenue per Visit of $139.81, an increase of 3.9% from $134.50 in Q2 2023 | |
| · | Total occupational health centers of 547, compared to 540 at end of Q2 2023 | |
| · | Total onsite health clinics of 154, compared to 141 at end of Q2 2023 |
Company Overview
Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our 11,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care, to more than 50,000 patients each day on average across 45 states at our 547 occupational health centers, 154 onsite health clinics at employer worksites, and Concentra Telemed as of June 30, 2024.
1
Second Quarter 2024 Financial Overview
For the second quarter ended June 30, 2024, revenue increased 2.3% to $477.9 million, compared to $467.1 million for the same quarter, prior year. Income from operations increased 2.2% to $83.9 million for the second quarter ended June 30, 2024, compared to $82.1 million for the same quarter, prior year. Net income decreased 1.8% to $53.1 million for the second quarter ended June 30, 2024, compared to $54.0 million for the same quarter, prior year. Adjusted EBITDA increased 1.2% to $101.6 million for the second quarter ended June 30, 2024, compared to $100.4 million for the same quarter, prior year. The Adjusted EBITDA margin was 21.3% for the second quarter ended June 30, 2024, compared to 21.5% for the same quarter, prior year. Earnings per common share decreased 2.0% to $0.50 for the second quarter ended June 30, 2024, compared to $0.51 for the same quarter, prior year. Adjusted earnings per share was $0.49 for the second quarter ended June 30, 2024, compared to $0.51 for the same quarter, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release. A reconciliation of earnings per common share to adjusted earnings per share is presented in table XI of this release.
Year to Date June 30, 2024 Financial Overview
For the six months ended June 30, 2024, revenue increased 2.4% to $945.5 million, compared to $923.4 million for the same period, prior year. Income from operations increased 1.3% to $159.4 million for the six months ended June 30, 2024, compared to $157.4 million for the same period, prior year. Net income increased 1.8% to $103.3 million for the six months ended June 30, 2024, compared to $101.5 million for the same period, prior year. Adjusted EBITDA increased 1.9% to $197.7 million for the six months ended June 30, 2024, compared to $194.1 million for the same period, prior year. The Adjusted EBITDA margin was 20.9% for the six months ended June 30, 2024, compared to 21.0% for the same period, prior year. Earnings per share increased 2.1% to $0.97 for the six months ended June 30, 2024, compared to $0.95 for the same period, prior year. Adjusted earnings per common share was $0.98 for the six months ended June 30, 2024, compared to $0.95 for the same period, prior year. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table X of this release. A reconciliation of earnings per share to adjusted earnings per common share is presented in table XI of this release.
Balance Sheet
As of June 30, 2024, Concentra’s balance sheet reflected cash of $50.7 million, total debt of $427.7 million and total assets of $2.363 billion.
Cash Flow
Cash flows provided by operating activities in the second quarter ended June 30, 2024 totaled $70.4 million compared to $81.8 million for the same quarter, prior year. During the second quarter ended June 30, 2024, capital expenditures totaled $15.3 million, excluding acquisitions.
Initial Public Offering and Debt Transactions
On July 26, 2024, Concentra completed an initial public offering (“IPO”) of 22,500,000 shares of its common stock, par value $0.01 per share, at an initial public offering price of $23.50 per share for gross proceeds of $528.8 million. In addition, Concentra has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of its common stock. Concentra shares began trading on the New York Stock Exchange under the symbol “CON” on July 25, 2024. In connection with the offering, Concentra Health Services, Inc. (“CHSI”), a wholly-owned subsidiary of Concentra, entered into certain financing arrangements which include Credit Facilities and $650.0 million aggregate principal amount of 6.875% Senior Notes due 2032 (the “Notes”). The Notes are unconditionally guaranteed, jointly and severally, on a senior unsecured basis by Concentra and certain of its wholly-owned subsidiaries. The Credit Facilities consist of an $850.0 million Term Loan and a $400.0 million Revolving Credit Facility. The Term Loan matures on July 26, 2031 and has an interest rate of Term SOFR plus 2.25%, subject to a leverage-based pricing grid. The Revolving Credit Facility matures on July 26, 2029 and has an interest rate of Term SOFR plus 2.50%, subject to a leverage-based pricing grid.
The net proceeds of the IPO were used to pay down the long-term debt and promissory note with a related party and the debt financing transactions, except for $34.7 million, were used to issue a dividend to Select Medical Corporation.
2
This recapitalization results in $1.5 billion in total debt and $100 million in cash on our balance sheet, or total net debt of $1.4 billion. With the $400 million revolver, we have $500 million in total liquidity.
Conference Call
Concentra will host a conference call regarding its second quarter results and its business outlook on Friday, August 2, 2024, at 10:30 am ET. The conference call will be a live webcast and can be accessed at Concentra Group Holdings Parent, Inc.’s website at www.concentra.com and a replay of the webcast will be available shortly after the call through the same link.
For listeners wishing to dial-in via telephone, or participate in the question and answer session, you may pre-register for the call at Concentra Earnings Call Registration to obtain your dial-in number and unique passcode.
3
* * * * *
Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:
| · | The frequency of work-related injuries and illnesses; |
| · | The adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks; |
| · | Changes to regulations, new interpretations of existing regulations, or violations of regulations; |
| · | State fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors; |
| · | Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs; |
| · | Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs; |
| · | Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers; |
| · | A security breach of our, or our third-party vendors’, information technology systems which may cause a violation of HIPAA and subject us to potential legal and reputational harm; |
| · | Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes; |
| · | Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements and the effects of claims asserted against us could subject us to substantial uninsured liabilities; |
| · | Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities; |
| · | Our exposure to additional risk due to our reliance on third parties in many aspects of our business; |
| · | Compliance with applicable laws regarding the corporate practice of medicine and therapy and fee-splitting; |
| · | Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information; |
| · | Compliance with applicable data interoperability and information blocking rule; |
| · | Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations; |
| · | Our ability to adequately protect and enforce our intellectual property and other proprietary rights; |
| · | Adverse economic conditions in the U.S. or globally; |
| · | Any negative impact on the global economy and capital markets resulting from other geopolitical tensions; |
| · | Our ability to maintain satisfactory credit ratings; |
| · | The inability to execute on the separation from Select Medical; |
| · | The risk of disruption or unanticipated costs in connection with the separation; |
| · | Our ability to succeed as a standalone publicly traded entity; |
4
| · | Restrictions on our business, potential tax and indemnification liabilities and substantial charges in connection with the separation, the distribution and related transactions; |
| · | The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease similar to the COVID-19 pandemic; |
| · | The loss of key members of our management team and our ability to attract and retain talented, highly skilled employees and a diverse workforce, and on the succession of our senior management; and, |
| · | Changes in tax laws or exposures to additional tax liabilities. |
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.
Investor inquiries:
Bill Chapman
Vice President, Strategy & Investor Relations
972-725-6488
ir@concentra.com
SOURCE: Concentra Group Holdings Parent, Inc.
5
I. Condensed Consolidated Statements of Operations
For the Second Quarter Ended June 30, 2024 and 2023
(In thousands, except per share amounts, unaudited)
| 2024 | 2023 | % Change | ||||||||||
| Revenue | $ | 477,915 | $ | 467,079 | 2.3 | % | ||||||
| Costs and expenses: | ||||||||||||
| Cost of services, exclusive of depreciation and amortization | 339,273 | 329,836 | 2.9 | |||||||||
| General and administrative, exclusive of depreciation and amortization (1) | 36,828 | 37,003 | (0.5 | ) | ||||||||
| Depreciation and amortization | 17,870 | 18,283 | (2.3 | ) | ||||||||
| Total costs and expenses | 393,971 | 385,122 | 2.3 | |||||||||
| Other operating income | — | 151 | N/M | |||||||||
| Income from operations | 83,944 | 82,108 | 2.2 | |||||||||
| Other income and expense: | ||||||||||||
| Equity in losses of unconsolidated subsidiaries | (3,676 | ) | — | N/M | ||||||||
| Interest expense on related party debt | (9,318 | ) | (11,500 | ) | (19.0 | ) | ||||||
| Interest income | 205 | 17 | N/M | |||||||||
| Income before income taxes | 71,155 | 70,625 | 0.8 | |||||||||
| Income tax expense | 18,096 | 16,593 | 9.1 | |||||||||
| Net income | 53,059 | 54,032 | (1.8 | ) | ||||||||
| Less: Net income attributable to non-controlling interests | 1,322 | 1,290 | 2.5 | |||||||||
| Net income attributable to Concentra | $ | 51,737 | $ | 52,742 | (1.9 | )% | ||||||
| Basic and diluted earnings per common share:(2) | $ | 0.50 | $ | 0.51 | ||||||||
| (1) | Includes the shared service fee from related party of $3.8 million and $3.7 million for the second quarter ended June 30, 2024 and 2023, respectively. |
| (2) | Refer to table III for calculation of earnings per common share. |
| N/M | Not meaningful |
6
II. Condensed Consolidated Statements of Operations
For the Six Months Ended June 30, 2024 and 2023
(In thousands, except per share amounts, unaudited)
| 2024 | 2023 | % Change | ||||||||||
| Revenue | $ | 945,513 | $ | 923,377 | 2.4 | % | ||||||
| Costs and expenses: | ||||||||||||
| Cost of services, exclusive of depreciation and amortization | 676,263 | 657,914 | 2.8 | |||||||||
| General and administrative, exclusive of depreciation and amortization (1) | 73,737 | 71,653 | 2.9 | |||||||||
| Depreciation and amortization | 36,355 | 36,593 | (0.7 | ) | ||||||||
| Total costs and expenses | 786,355 | 766,160 | 2.6 | |||||||||
| Other operating income | 284 | 151 | N/M | |||||||||
| Income from operations | 159,442 | 157,368 | 1.3 | |||||||||
| Other income and expense: | ||||||||||||
| Equity in losses of unconsolidated subsidiaries | (3,676 | ) | (526 | ) | N/M | |||||||
| Interest expense on related party debt | (19,289 | ) | (22,576 | ) | (14.6 | ) | ||||||
| Interest income (expense) | 94 | (44 | ) | N/M | ||||||||
| Income before income taxes | 136,571 | 134,222 | 1.8 | |||||||||
| Income tax expense | 33,233 | 32,759 | 1.4 | |||||||||
| Net income | 103,338 | 101,463 | 1.8 | |||||||||
| Less: Net income attributable to non-controlling interests | 2,645 | 2,457 | 7.7 | |||||||||
| Net income attributable to Concentra | $ | 100,693 | $ | 99,006 | 1.7 | % | ||||||
| Basic and diluted earnings per common share:(2) | $ | 0.97 | $ | 0.95 | ||||||||
| (1) | Includes the shared service fee from related party of $7.7 million and $7.3 million for the six months ended June 30, 2024 and 2023, respectively. |
| (2) | Refer to table III for calculation of earnings per common share. |
| N/M | Not meaningful |
7
III. Earnings per Share
For the Three and Six Months Ended June 30, 2024 and 2023
(In thousands, except per share amounts, unaudited)
At December 31, 2023, there were 435,000 Class A units, 8,498 Class B units, and 3,583 Class C units (in thousands) outstanding which converted to common shares on a one-for-one basis effective March 4, 2024. On June 24, 2024, the Company effectuated a reverse stock split at a ratio of one share of common stock for every 4.295 shares of common stock and resulted in 104,094 shares (in thousands) outstanding. There were no participating shares or securities outstanding during the three and six months ended June 30, 2024.
The following table sets forth the computation of earnings per share (EPS):
| Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | ||||||||||||||||||||||
| Net Income Attributable to Concentra |
Shares(1) | Basic and Diluted EPS |
Net Income Attributable to Concentra |
Shares(1) | Basic and Diluted EPS |
||||||||||||||||||
| (in thousands, except for per share amounts) | |||||||||||||||||||||||
| Common shares | $ | 51,737 | 104,094 | $ | 0.50 | $ | 100,693 | 104,094 | $ | 0.97 | |||||||||||||
At June 30, 2023, Concentra’s capital structure included Class A, B and C units outstanding and unvested restricted interests and outstanding options. To calculate EPS for the three and six months ended June 30, 2023, Concentra applied the two-class method because its unvested restricted interests and outstanding options are participating securities.
The following table sets forth the net income attributable to the Company, its units outstanding, and its participating units outstanding:
|
Three Months June 30, 2023 |
Six Months June 30, 2023 |
|||||||
| (in thousands) | ||||||||
| Net income | $ | 54,032 | $ | 101,463 | ||||
| Less: net income attributable to non-controlling interests | 1,290 | 2,457 | ||||||
| Net income attributable to Concentra | 52,742 | 99,006 | ||||||
| Less: Distributed and undistributed income attributable to participating shares | 148 | 287 | ||||||
| Distributed and undistributed income attributable to outstanding shares | $ | 52,594 | $ | 98,719 | ||||
The following table sets forth the computation of EPS, under the two-class method:
| Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 | |||||||||||||||||||||||
| Net Income Allocation |
Shares (1)(2) |
Basic and Diluted EPS |
Net Income Allocation |
Shares (1)(2) |
Basic and Diluted EPS |
|||||||||||||||||||
| (in thousands, except for per share amounts) | ||||||||||||||||||||||||
| Outstanding Class A, Class B, and Class C shares | $ | 52,594 | 103,962 | $ | 0.51 | $ | 98,719 | 103,952 | $ | 0.95 | ||||||||||||||
| Participating shares | 148 | 292 | $ | 0.51 | 287 | 302 | $ | 0.95 | ||||||||||||||||
| Total Company | $ | 52,742 | $ | 99,006 | ||||||||||||||||||||
| (1) | The recapitalization of the members units into common shares has been treated as such for earnings per share purposes and has been reflected retrospectively for all periods, along with the one for 4.295 reverse stock split. |
| (2) | Represents the weighted average units outstanding during the period. |
8
IV. Condensed Consolidated Balance Sheets
(In thousands, unaudited)
| June 30, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 50,669 | $ | 31,374 | ||||
| Accounts receivable | 228,964 | 216,194 | ||||||
| Other current assets | 40,673 | 46,850 | ||||||
| Total Current Assets | 320,306 | 294,418 | ||||||
| Operating lease right-of-use assets | 399,464 | 397,852 | ||||||
| Property and equipment, net | 186,879 | 178,370 | ||||||
| Goodwill | 1,233,406 | 1,229,745 | ||||||
| Identifiable intangible assets, net | 212,868 | 224,769 | ||||||
| Other assets | 10,415 | 8,406 | ||||||
| Total Assets | $ | 2,363,338 | $ | 2,333,560 | ||||
| Liabilities and Equity | ||||||||
| Current Liabilities: | ||||||||
| Payables and accruals | $ | 182,594 | $ | 196,879 | ||||
| Due to related party | 4,360 | 3,354 | ||||||
| Current operating lease liabilities | 73,517 | 72,946 | ||||||
| Current portion of long-term debt and notes payable | 4,682 | 1,455 | ||||||
| Total Current Liabilities | 265,153 | 274,634 | ||||||
| Non-current operating lease liabilities | 359,736 | 357,310 | ||||||
| Long-term debt, net of current portion | 3,048 | 3,291 | ||||||
| Long-term debt with related party | 420,000 | 470,000 | ||||||
| Non-current deferred tax liability | 21,994 | 23,364 | ||||||
| Other non-current liabilities | 23,015 | 27,522 | ||||||
| Total Liabilities | 1,092,946 | 1,156,121 | ||||||
| Redeemable non-controlling interests | 18,410 | 16,477 | ||||||
| Total equity | 1,251,982 | 1,160,962 | ||||||
| Total Liabilities and Equity | $ | 2,363,338 | $ | 2,333,560 | ||||
9
V. Condensed Consolidated Statements of Cash Flows
For the Three Months Ended June 30, 2024 and 2023
(In thousands, unaudited)
| 2024 | 2023 | |||||||
| Operating activities | ||||||||
| Net income | $ | 53,059 | $ | 54,032 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 17,870 | 18,283 | ||||||
| Provision for expected credit losses | 47 | 166 | ||||||
| Equity in losses of unconsolidated subsidiaries | 3,676 | — | ||||||
| Gain on sale or disposal of assets | (1 | ) | (10 | ) | ||||
| Stock compensation expense | 166 | — | ||||||
| Deferred income taxes | 903 | (70 | ) | |||||
| Changes in operating assets and liabilities, net of effects of business combinations: | ||||||||
| Accounts receivable | 676 | (7,650 | ) | |||||
| Other current assets | 8,539 | 2,711 | ||||||
| Other assets | (4,939 | ) | 622 | |||||
| Accounts payable and accrued liabilities | (9,563 | ) | 13,762 | |||||
| Net cash provided by operating activities | 70,433 | 81,846 | ||||||
| Investing activities | ||||||||
| Business combinations, net of cash acquired | — | (1,446 | ) | |||||
| Acquired customer relationships | — | (1,626 | ) | |||||
| Purchases of property and equipment | (15,263 | ) | (14,220 | ) | ||||
| Proceeds from sale of assets | 1 | 16 | ||||||
| Net cash used in investing activities | (15,262 | ) | (17,276 | ) | ||||
| Financing activities | ||||||||
| Payments on related party revolving promissory note | (50,000 | ) | (50,000 | ) | ||||
| Principal payments on other debt | (2,103 | ) | (1,686 | ) | ||||
| Distributions to and purchases of non-controlling interests | (1,100 | ) | (1,253 | ) | ||||
| Distributions to Parent | (851 | ) | (3,352 | ) | ||||
| Net cash used in financing activities | (54,054 | ) | (56,291 | ) | ||||
| Net increase in cash and cash equivalents | 1,117 | 8,279 | ||||||
| Cash and cash equivalents at beginning of period | 49,552 | 24,959 | ||||||
| Cash and cash equivalents at end of period | $ | 50,669 | $ | 33,238 | ||||
| Supplemental information | ||||||||
| Cash paid for interest | $ | 9,554 | $ | 11,477 | ||||
| Cash paid for taxes | 33,975 | 32,650 | ||||||
10
VI. Condensed Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2024 and 2023
(In thousands, unaudited)
| 2024 | 2023 | |||||||
| Operating activities | ||||||||
| Net income | $ | 103,338 | $ | 101,463 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 36,355 | 36,593 | ||||||
| Provision for expected credit losses | 59 | 185 | ||||||
| Equity in losses of unconsolidated subsidiaries | 3,676 | 526 | ||||||
| (Gain) loss on sale or disposal of assets | 42 | (14 | ) | |||||
| Stock compensation expense | 332 | 178 | ||||||
| Deferred income taxes | (1,618 | ) | (3,265 | ) | ||||
| Changes in operating assets and liabilities, net of effects of business combinations: | ||||||||
| Accounts receivable | (12,829 | ) | (27,011 | ) | ||||
| Other current assets | 1,224 | (9,944 | ) | |||||
| Other assets | (4,217 | ) | 1,796 | |||||
| Accounts payable and accrued liabilities | (11,307 | ) | (966 | ) | ||||
| Net cash provided by operating activities | 115,055 | 99,541 | ||||||
| Investing activities | ||||||||
| Business combinations, net of cash acquired | (5,144 | ) | (1,446 | ) | ||||
| Acquired customer relationships | — | (4,382 | ) | |||||
| Purchases of property and equipment | (32,494 | ) | (25,864 | ) | ||||
| Proceeds from sale of assets | 23 | 20 | ||||||
| Net cash used in investing activities | (37,615 | ) | (31,672 | ) | ||||
| Financing activities | ||||||||
| Borrowings from related party revolving promissory note | 10,000 | — | ||||||
| Payments on related party revolving promissory note | (60,000 | ) | (70,000 | ) | ||||
| Borrowings of other debt | 6,618 | 5,471 | ||||||
| Principal payments on other debt | (4,379 | ) | (4,074 | ) | ||||
| Distributions to and purchases of non-controlling interests | (2,643 | ) | (3,130 | ) | ||||
| Distributions to Parent | (7,741 | ) | (555 | ) | ||||
| Net cash used in financing activities | (58,145 | ) | (72,288 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 19,295 | (4,419 | ) | |||||
| Cash and cash equivalents at beginning of period | 31,374 | 37,657 | ||||||
| Cash and cash equivalents at end of period | $ | 50,669 | $ | 33,238 | ||||
| Supplemental information | ||||||||
| Cash paid for interest | $ | 19,512 | $ | 22,784 | ||||
| Cash paid for taxes | 34,009 | 32,445 | ||||||
11
VII. Key Statistics
For the Second Quarter Ended June 30, 2024 and 2023
(unaudited)
| 2024 | 2023 | % Change | ||||||||||
| Facility Count | ||||||||||||
| Number of occupational health centers—start of period | 547 | 539 | ||||||||||
| Number of occupational health centers acquired | — | 1 | ||||||||||
| Number of occupational health centers de novos | 1 | — | ||||||||||
| Number of occupational health centers closed/sold | (1 | ) | — | |||||||||
| Number of occupational health centers—end of period | 547 | 540 | ||||||||||
| Number of onsite health clinics operated—end of period | 154 | 141 | ||||||||||
| Number of patient visits (1)(2) | ||||||||||||
| Workers’ Compensation | 1,455,254 | 1,429,035 | 1.8 | % | ||||||||
| Employer Services | 1,702,399 | 1,781,012 | (4.4 | )% | ||||||||
| Consumer Health | 56,602 | 57,847 | (2.2 | )% | ||||||||
| Total | 3,214,255 | 3,267,894 | (1.6 | )% | ||||||||
| Visits per day volume | ||||||||||||
| Workers’ Compensation | 22,739 | 22,329 | 1.8 | % | ||||||||
| Employer Services | 26,600 | 27,828 | (4.4 | )% | ||||||||
| Consumer Health | 884 | 904 | (2.2 | )% | ||||||||
| Total | 50,223 | 51,061 | (1.6 | )% | ||||||||
| Revenue per visit (1)(3) | ||||||||||||
| Workers’ Compensation | $ | 198.18 | $ | 194.92 | 1.7 | % | ||||||
| Employer Services | 90.05 | 86.00 | 4.7 | % | ||||||||
| Consumer Health | 135.49 | 134.88 | 0.5 | % | ||||||||
| Total | $ | 139.81 | $ | 134.50 | 3.9 | % | ||||||
| Business Days (4) | 64 | 64 | ||||||||||
| (1) | Excludes onsite clinics. |
| (2) | Represents the number of visits in which patients were treated at Occupational Health Centers during the periods presented. |
| (3) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our Occupational Health Centers segment and does not include our Onsite Health Clinics or Other Businesses segments. |
| (4) | Represents the number of days in which normal business operations were conducted during the periods presented. |
12
VIII. Key Statistics
For the Six Months Ended June 30, 2024 and 2023
(unaudited)
| 2024 | 2023 | % Change | ||||||||||
| Facility Count | ||||||||||||
| Number of occupational health centers—start of period | 544 | 540 | ||||||||||
| Number of occupational health centers acquired | 2 | 1 | ||||||||||
| Number of occupational health centers de novos | 2 | — | ||||||||||
| Number of occupational health centers closed/sold | (1 | ) | (1 | ) | ||||||||
| Number of occupational health centers—end of period | 547 | 540 | ||||||||||
| Number of onsite health clinics operated—end of period | 154 | 141 | ||||||||||
| Number of patient visits (1)(2) | ||||||||||||
| Workers’ Compensation | 2,888,338 | 2,825,602 | 2.2 | % | ||||||||
| Employer Services | 3,361,690 | 3,541,543 | (5.1 | )% | ||||||||
| Consumer Health | 119,882 | 118,694 | 1.0 | % | ||||||||
| Total | 6,369,910 | 6,485,839 | (1.8 | )% | ||||||||
| Visits per day volume | ||||||||||||
| Workers’ Compensation | 22,565 | 22,075 | 2.2 | % | ||||||||
| Employer Services | 26,263 | 27,668 | (5.1 | )% | ||||||||
| Consumer Health | 937 | 928 | 1.0 | % | ||||||||
| Total | 49,765 | 50,671 | (1.8 | )% | ||||||||
| Revenue per visit (1)(3) | ||||||||||||
| Workers’ Compensation | $ | 196.75 | $ | 193.55 | 1.7 | % | ||||||
| Employer Services | 90.44 | 86.22 | 4.9 | % | ||||||||
| Consumer Health | 133.42 | 134.70 | (1.0 | )% | ||||||||
| Total | $ | 139.45 | $ | 133.86 | 4.2 | % | ||||||
| Business Days (4) | 128 | 128 | ||||||||||
| (1) | Excludes onsite clinics. |
| (2) | Represents the number of visits in which patients were treated at Occupational Health Centers during the periods presented. |
| (3) | Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our Occupational Health Centers segment and does not include our Onsite Health Clinics or Other Businesses segments. |
| (4) | Represents the number of days in which normal business operations were conducted during the periods presented. |
13
IX. Disaggregated Revenue
For the Three and Six Months Ended June 30, 2024 and 2023
(In thousands, unaudited)
The following table disaggregates the Company’s revenue for the three and six months ended June 30, 2024 and 2023:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Occupational health centers: | ||||||||||||||||
| Workers' compensation | $ | 288,405 | $ | 278,554 | $ | 568,271 | $ | 546,894 | ||||||||
| Employer services | 153,305 | 153,164 | 304,040 | 305,337 | ||||||||||||
| Consumer health | 7,669 | 7,802 | 15,995 | 15,987 | ||||||||||||
| Other occupational health center revenue | 1,861 | 2,254 | 4,006 | 4,672 | ||||||||||||
| Total occupational health center revenue | 451,240 | 441,774 | 892,312 | 872,890 | ||||||||||||
| Onsite clinics | 15,539 | 14,705 | 31,396 | 29,250 | ||||||||||||
| Other | 11,136 | 10,600 | 21,805 | 21,237 | ||||||||||||
| Total revenue | $ | 477,915 | $ | 467,079 | $ | 945,513 | $ | 923,377 | ||||||||
14
X. Net Income to Adjusted EBITDA Reconciliation
For the Three and Six Months Ended June 30, 2024 and 2023
(In thousands, unaudited)
The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our segments. Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States of America (“GAAP”). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.
The following table reconciles net income to Adjusted EBITDA for Concentra. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net income | $ | 53,059 | $ | 54,032 | $ | 103,338 | $ | 101,463 | ||||||||
| Income tax expense | 18,096 | 16,593 | 33,233 | 32,759 | ||||||||||||
| Interest (income) expense | (205 | ) | (17 | ) | (94 | ) | 44 | |||||||||
| Interest expense on related party debt | 9,318 | 11,500 | 19,289 | 22,576 | ||||||||||||
| Equity in losses of unconsolidated subsidiaries | 3,676 | — | 3,676 | 526 | ||||||||||||
| Stock compensation expense | 166 | — | 332 | 178 | ||||||||||||
| Depreciation and amortization | 17,870 | 18,283 | 36,355 | 36,593 | ||||||||||||
| Separation transaction costs (1) | (380 | ) | — | 1,613 | — | |||||||||||
| Adjusted EBITDA | $ | 101,600 | $ | 100,391 | $ | 197,742 | $ | 194,139 | ||||||||
| Adjusted EBITDA margin | 21.3 | % | 21.5 | % | 20.9 | % | 21.0 | % | ||||||||
| (1) | Separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company’s planned separation into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations. During the three months ended June 30, 2024, an adjustment was made to capitalize certain separation transaction costs recognized during the first quarter of 2024. |
15
XI. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share
For the Three and Six Months Ended June 30, 2024 and 2023
(In thousands, except per share amounts, unaudited)
Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP. Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Concentra believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of Concentra’s ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies.
The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis.
| Three Months Ended June 30, | ||||||||||||||||
| 2024 | Per Share(1) | 2023 | Per Share(1) | |||||||||||||
| Net income attributable to common shares(1) | $ | 51,737 | $ | 0.50 | $ | 52,594 | $ | 0.51 | ||||||||
| Adjustments:(2) | ||||||||||||||||
| Separation transaction costs, net of tax | (287 | ) | 0.00 | — | — | |||||||||||
| Adjusted net income attributable to common shares | $ | 51,450 | $ | 0.49 | (3) | $ | 52,594 | $ | 0.51 | |||||||
| Six Months Ended June 30, | ||||||||||||||||
| 2024 | Per Share(1) | 2023 | Per Share(1) | |||||||||||||
| Net income attributable to common shares(1) | $ | 100,693 | $ | 0.97 | $ | 98,719 | $ | 0.95 | ||||||||
| Adjustments:(2) | ||||||||||||||||
| Separation transaction costs, net of tax | 1,213 | 0.01 | — | — | ||||||||||||
| Adjusted net income attributable to common shares | $ | 101,906 | $ | 0.98 | $ | 98,719 | $ | 0.95 | ||||||||
| (1) | Net income attributable to common shares and earnings per common share are calculated based on the weighted average common shares outstanding, as presented in table III. |
| (2) | Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest impacts and are calculated based on the diluted weighted average common shares outstanding. The estimated income tax impact, which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes both current and deferred income tax expense or benefit. |
| (3) | Does not total due to rounding. |
16